Adrenergic beta-antagonist: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (Started heart failure section) |
||
| Line 2: | Line 2: | ||
'''Adrenergic beta-receptor blockaders''' ('''beta-blockers''') are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of [[hypertension]], cardiac arrhythmias, angina pectoris, glaucoma, [[migraine]] headaches, and anxiety".<ref>{{MeSH}}</ref> | '''Adrenergic beta-receptor blockaders''' ('''beta-blockers''') are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of [[hypertension]], cardiac arrhythmias, angina pectoris, glaucoma, [[migraine]] headaches, and anxiety".<ref>{{MeSH}}</ref> | ||
Beta-blockers vary within the class regarding their properties. Beta-blockers that have low intrinsic sympathomimetic activity (ISA), low membrane stabilizing activity, high [[Adrenergic receptor|beta 1-selectivity]], and high lipophilicity may be more effective.<ref name="pmid9122425">{{cite journal |author=Soriano JB, Hoes AW, Meems L, Grobbee DE |title=Increased survival with beta-blockers: importance of ancillary properties |journal=Prog Cardiovasc Dis |volume=39 |issue=5 |pages=445–56 |year=1997 |pmid=9122425 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0033-0620(97)80039-4 |issn=}}</ref | Beta-blockers vary within the class regarding their properties. Beta-blockers that have low intrinsic sympathomimetic activity (ISA), low membrane stabilizing activity, high [[Adrenergic receptor|beta 1-selectivity]], and high lipophilicity may be more effective.<ref name="pmid9122425">{{cite journal |author=Soriano JB, Hoes AW, Meems L, Grobbee DE |title=Increased survival with beta-blockers: importance of ancillary properties |journal=Prog Cardiovasc Dis |volume=39 |issue=5 |pages=445–56 |year=1997 |pmid=9122425 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0033-0620(97)80039-4 |issn=}}</ref> | ||
==Pharmacogenomics== | ==Pharmacogenomics== | ||
| Line 33: | Line 33: | ||
|chapterurl=http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=ebm&part=bb | |chapterurl=http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=ebm&part=bb | ||
|language= |publisher=National Library of Medicine (US), National Center for Biotechnology Information |location=Bethesda (MD) |year=2007 |origyear= |pages= |quote=Based on http://www.ohsu.edu/drugeffectiveness/ |isbn= |oclc= |doi= |url=http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=ebm |accessdate=}}</ref> | |language= |publisher=National Library of Medicine (US), National Center for Biotechnology Information |location=Bethesda (MD) |year=2007 |origyear= |pages= |quote=Based on http://www.ohsu.edu/drugeffectiveness/ |isbn= |oclc= |doi= |url=http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=ebm |accessdate=}}</ref> | ||
===Coronary heart disease=== | |||
{{main|Coronary heart disease}} | |||
A [[meta-analysis]] has concluded that [[metoprolol]] may be the best beta-blocker for [[secondary prevention]] of [[myocardial infarction]].<ref name="pmid9122425"/> | |||
===Heart failure=== | |||
{{main|Heart failure}} | |||
Two [[cohort study|cohort studies]] suggest that [[atenolol]] and [[carvedilol]] may be more effect than metoprolol for the treatment of heart failure.<ref name="pmid19064824">{{cite journal |author=Kramer JM, Curtis LH, Dupree CS, ''et al'' |title=Comparative effectiveness of beta-blockers in elderly patients with heart failure |journal=Arch. Intern. Med. |volume=168 |issue=22 |pages=2422–8; discussion 2428–32 |year=2008 |month=December |pmid=19064824 |doi=10.1001/archinternmed.2008.511 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=19064824 |issn=}}</ref><ref name="pmid19064823">{{cite journal |author=Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R |title=Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice |journal=Arch. Intern. Med. |volume=168 |issue=22 |pages=2415–21 |year=2008 |month=December |pmid=19064823 |doi=10.1001/archinternmed.2008.506 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=19064823 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 12:11, 23 December 2008
Adrenergic beta-receptor blockaders (beta-blockers) are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety".[1]
Beta-blockers vary within the class regarding their properties. Beta-blockers that have low intrinsic sympathomimetic activity (ISA), low membrane stabilizing activity, high beta 1-selectivity, and high lipophilicity may be more effective.[2]
Pharmacogenomics
Regarding he treatment of heart failure, there is conflicting evidence whether beta-blockers are as effective in African-American patients as in Anglo patients.[3] This may be due to a polymorphism in African-American patients of the G protein–coupled cell surface receptor kinase (GRK5) (OMIM) that confers a natural "genetic beta-blockade".[4]
Availability
Generically available beta-blockers include:[5][6]
- Betaxolol
- Nadolol
- Propranolol
- Timolol
Generic beta-blockers with beta 1-selectivity:[2]
- Atenolol (less lipid soluble; renally excreted)
- Bisoprolol
- Metoprolol (hepatically metabolized by cytochrome P-450)
Generic beta-blockers with intrinsic sympathomimetic activity (less resting bradycardia and lipid changes):[5]
- Acebutolol
- Pindolol
Generic beta-blockers with alpha blocking activity (more orthostatic hypotension):[5]
- Carvedilol
- Labetalol
Clinical uses
The individual beta-blockers have been compared in the treatment of various diseases.[7]
Coronary heart disease
A meta-analysis has concluded that metoprolol may be the best beta-blocker for secondary prevention of myocardial infarction.[2]
Heart failure
Two cohort studies suggest that atenolol and carvedilol may be more effect than metoprolol for the treatment of heart failure.[8][9]
References
- ↑ Anonymous (2024), Adrenergic beta-antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 2.2 Soriano JB, Hoes AW, Meems L, Grobbee DE (1997). "Increased survival with beta-blockers: importance of ancillary properties". Prog Cardiovasc Dis 39 (5): 445–56. PMID 9122425. [e]
- ↑ Shekelle PG, Rich MW, Morton SC, et al (2003). "Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials". J. Am. Coll. Cardiol. 41 (9): 1529–38. PMID 12742294. [e]
- ↑ Liggett, Stephen B et al. 2008. A GRK5 polymorphism that inhibits [beta]-adrenergic receptor signaling is protective in heart failure. Nat Med advanced online publication. http://dx.doi.org/10.1038/nm1750 (Accessed April 29, 2008).
- ↑ 5.0 5.1 5.2 (June 2005) "Drugs for hypertension". Treat Guidel Med Lett 3 (34): 39–48. PMID 15912125. [e]
- ↑ (March 2008) "Nebivolol (Bystolic) for hypertension". Med Lett Drugs Ther 50 (1281): 17–9. PMID 18323772. [e]
- ↑ Dean L (2007). “Comparing Beta Blockers”, PubMed Clinical Q&A. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. “Based on http://www.ohsu.edu/drugeffectiveness/”
- ↑ Kramer JM, Curtis LH, Dupree CS, et al (December 2008). "Comparative effectiveness of beta-blockers in elderly patients with heart failure". Arch. Intern. Med. 168 (22): 2422–8; discussion 2428–32. DOI:10.1001/archinternmed.2008.511. PMID 19064824. Research Blogging.
- ↑ Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R (December 2008). "Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice". Arch. Intern. Med. 168 (22): 2415–21. DOI:10.1001/archinternmed.2008.506. PMID 19064823. Research Blogging.